CliffBio
biologic

Evenity

romosozumab-aqqg

Loss of exclusivityApril 2031projected — 12-year biologic exclusivity estimate
CompanyAmgen →See this company's full patent-cliff portfolio

Drug detail

Brand nameEvenity
Active ingredientromosozumab-aqqg
Strength105MG/1.17ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalApril 2019
Marketing statusRx

More from Amgen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Evenity patent cliff — loss of exclusivity April 2031 | CliffBio